1. Haddad C. Embodied values: post-pharmaceutical health and the accumulation of surplus vitality in regenerative stem cell medicine. Sociologias 2019; 21:48–79. https://doi.org/10.1590/15174522-02105002
2. Organisation for Economic Co-operation and Development -OECD. Scoping document. The bioeconomy to 2030: Designing a policy agenda. Paris,France: 2006. https://web-archive.oecd.org/2012-06-15/144237-36972476.pdf.
3. Commission of the European Communities. Life Sciences and Biotechnology – a strategy for Europe: Communication from the Commission to the European Parliament, the Council, the Economic and Social Committee and the Committee of the Regions. Brussels, Belgium: 2002. https://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2002/0027/COM_COM(2002)0027_EN.pdf.
4. Organisation for Economic Co-operation and Development - OECD. The Bioeconomy to 2030: Designing a policy agenda. Paris, France: 2009. https://www.oecd-ilibrary.org/economics/the-bioeconomy-to-2030_9789264056886-en
5. Cooper M. Life as Surplus: Biotechnology and capitalism in the neoliberal era. 1st ed. Washington, USA: University of Washington Press; 2008.